To our knowledge, no reports have mentioned the signaling pathways activated by miR-936/Pim-3, and little is known about the precise mechanisms underlying the progression of sorafenib resistance triggered by miR-936/Pim-3 in liver cancer. The gene discussed is PIM3; the disease is liver cancer.